Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)-Reference-Cited by-同舟云学术

Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)

Published:2020-11-07 Issue:2 Volume:39 Page:530-536
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Otani Sakiko,Sasaki Jiichiro,Nakahara Yoshiro,Fukui Tomoya,Igawa Satoshi,Naoki Katsuhiko,Bessho Akihiro,Hosokawa Shinobu,Fukamatsu Nobuaki,Nakamura Yukiko,Kasai Takashi,Sugiyama Tomohide,Tokito Takaaki,Seki Nobuhiko,Hamada Akinobu,Okamoto Hiroaki,Masuda Noriyuki

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-020-01031-z.pdf

Reference27 articles.

1. Devesa SS, Bray F, Vizcaino AP, Parkin DM (2005) International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117(2):294–299. https://doi.org/10.1002/ijc.21183 published Online First: Epub Date]|

2. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98. https://doi.org/10.1056/NEJMoa011954 published Online First: Epub Date

3. Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol, published Online First: Epub Date 19(13):3210–3218. https://doi.org/10.1200/JCO.2001.19.13.3210

4. Scagliotti GV, De Marinis F, Rinaldi M et al (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20(21):4285–4291. https://doi.org/10.1200/JCO.2002.02.068 published Online First: Epub Date

5. Reck M, Popat S, Reinmuth N, Ruysscher DD, Kerr KM, Peters S. on behalf of the ESMO Guidelines Working Group Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014;25:pp. iii27–iii39